Absci Stock Plunges 7% After Its Quarterly Loss Widens

Research spending rose as Absci advanced its own drug programs, with interim hair-regrowth data expected in December.

Share
Absci Stock Plunges 7% After Its Quarterly Loss Widens

Absci, which designs antibody medicines with AI and tests them in the laboratory, plunged 7.3% to $9.38 in Thursday trading, as of 10:00 AM ET, erasing $127 million in market value. The decline followed a wider net loss and lower third-quarter revenue reported in the company's Thursday SEC filing.

A Hair-Regrowth Benchmark Clarified

Management clarified on Thursday's earnings call that its commercial benchmark for hair-regrowth efficacy continues to apply to thicker hairs. Absci's lead drug candidate, ABS-201, is in clinical testing for pattern hair loss and is also being developed for endometriosis.

The company expects interim hair-regrowth data in December, with longer-term results in early 2027. In June, Absci said early safety findings suggested the treatment was well tolerated; the planned regrowth assessment addresses whether it works.

More Spending On Absci's Own Medicines

The $19.2 million spent on research a year earlier was surpassed by the latest research spending of $23.6 million. Absci attributed most of the increase to advancing its internally developed drug programs.

Absci develops medicines of its own and works on drug discovery for pharmaceutical and biotechnology partners, including Merck, AstraZeneca and Almirall. Those collaborations can bring upfront payments, research fees, milestone payments and royalties.

The company was advancing five wholly owned internal programs as of December 31, 2025, along with additional early-discovery work. Its platform combines AI molecule design with laboratory validation.

The chief commercial officer role at Absci went to Gerry Muhle, who previously served as an executive at Galderma. “we have begun building our commercial infrastructure to support this and potential future programs,” said Founder and CEO Sean McClain.

A Sharp Drop After A Big Run

Thursday's decline was on pace to be Absci's fourth drop of 7% or more this month. Its market value stood at about $1.6 billion in Thursday trading.

Absci shares were up 190% year-to-date at Wednesday's close, compared with an 11% gain for the S&P 500. Thursday's loss came against that substantial advance.

December's expected interim results will assess hair regrowth, following the early safety findings Absci described in June.

Sources

More on Absci

All Absci (ABSI) coverage →